Can Intensive Insulin Therapy Improve Outcomes of COVID-19 Patients
Status:
Completed
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Evaluation of the reciprocal relation between hyperglycemia/diabetes mellitus (HG/DM) and
COVID-19 disease and the effect of mode of insulin therapy; intensive (IIT) or conventional
(CIT) on patients' outcomes All patients admitted to the quarantine hospitals with
mild-severe COVID disease were evaluated using the COVID-GRAM Critical Illness Risk Score and
gave blood samples for estimation of random blood glucose. Diabetic patients and non-diabetic
patients with persistent HG were randomly divided according to mode of IT. Patients who were
free HG were included as control normoglycemic (NG) patients. Study outcomes included the
incidence of progress to critical illness and mortality rate (MR), and the effect of IT on
such outcomes